{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang LW"],"funding":["Scientific Research Foundation for Scholars of Hangzhou Normal University","the Ministry of Science and Technology of China (High-end foreign experts program","National Natural Science Foundation of China","Hangzhou City \"115\" plan to introduce overseas intelligence projects"],"pagination":["2491"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9029554"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(8)"],"pubmed_abstract":["As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pathways. Dysregulation of ATR has been found across different cancer types. In recent years, the inhibition of ATR has been proven to be effective in cancer therapy in preclinical and clinical studies. Importantly, tumor-specific alterations such as ATM loss and Cyclin E1 (CCNE1) amplification are more sensitive to ATR inhibition and are being exploited in synthetic lethality (SL) strategy. Besides SL, synergistic anticancer effects involving ATRi have been reported in an increasing number in recent years. This review focuses on the recent advances in different forms of synergistic antitumor effects, summarizes the pharmacological benefits and ongoing clinical trials behind the biological mechanism, and provides perspectives for future challenges and opportunities. The hope is to draw awareness to the community that targeting ATR should have great potential in developing effective anticancer medicines."],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)."],"pmcid":["PMC9029554"],"funding_grant_id":["82073686, 81730108, and 81973635","G20200217005 and G2021017004","2019QDL003","20200215 and 20210120"],"pubmed_authors":["Duan J","Xie T","Ye XY","Bai R","Mao ND","Wang LW","Jiang S","Hui Z","Yuan YH"],"additional_accession":[]},"is_claimable":false,"name":"Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).","description":"As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pathways. Dysregulation of ATR has been found across different cancer types. In recent years, the inhibition of ATR has been proven to be effective in cancer therapy in preclinical and clinical studies. Importantly, tumor-specific alterations such as ATM loss and Cyclin E1 (CCNE1) amplification are more sensitive to ATR inhibition and are being exploited in synthetic lethality (SL) strategy. Besides SL, synergistic anticancer effects involving ATRi have been reported in an increasing number in recent years. This review focuses on the recent advances in different forms of synergistic antitumor effects, summarizes the pharmacological benefits and ongoing clinical trials behind the biological mechanism, and provides perspectives for future challenges and opportunities. The hope is to draw awareness to the community that targeting ATR should have great potential in developing effective anticancer medicines.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-20T00:18:14.109Z","creation":"2025-02-19T01:54:06.031Z"},"accession":"S-EPMC9029554","cross_references":{"pubmed":["35458687"],"doi":["10.3390/molecules27082491"]}}